We believe that with the current Pan-Cancer Analysis of Whole Genomes (PCAWG) project involving classic glioma microenvironment biomarkers (i.e., IDH1), researchers will identify more specialized features of cancer immune genomes (59). This evidence concerns the gene IDH1 and cancer.